Good to have an extensive Q&A session with Ken and Yacov after the formal AGM. My notes from the meeting are
- CFDA for device and factory expected Q3 2018. They are still meeting with CFDA.
- Now the phone is available on line, they are seeking purchase orders. Currently manufactured in Israel, will be in China after factory is approved.
- Phone currently available via physician in US. The over the counter submission has been filed, but they are speaking to FDA about packaging and data suitable for consumer not physician.
-Gmed ‘phone’ is a stand alone measuring device, not a phone or jacket, it can be connected to any phone via Bluetooth.
-Still pursuing the US$10M loan facility from Chinese SOI that was in IPO prospectus.
-Yacov was in India two weeks ago meeting Tier 1 partners for India/Taiwan MOU. He knows the FCL chairman personally. He’s still confident.
-Marketing strategy for Patch in US is to use distribution networks for the heart monitor and call centre they bought last year.
They seem to be methodically developing the devices/technology, but get the feeling more cash will be needed before sales really kick into gear, either via a loan/grant or CR.
GMV Price at posting:
30.0¢ Sentiment: Buy Disclosure: Held